A comprehensive drug testing program was carried out during the 16 days of the 1988 Oiympic Winter Games in Calgary, Canada. State-of-the-art technology was applied, involving high-resolution gas chromatography, high-performance liquid chromatography, gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, fluorescence polarization immunoassay, and radioimmunoassay. Samples from selected athletes were screened for five drug classes: stimulants, narcotic analgesics, anabolic steroids, p-blockers, and diuretics. In addition, samples were also screened for local anesthetics, corticosteroids, /3-human choriogonadotropin, and cannabinoids. During the 16-day event, 428 urine samples were processed and 3090 screening procedures performed. We describe the methods for analysis at the Olympic Games and present the results. We tested samples from selected athletes for five classes of drugs, namely, stimulants, narcotic analgesics, anabolic steroids, p-blockers, and diuretics. Examples of drugs in these classes are presented in Table 1 . We also tested for probenecid, which has been used in sports as a masking agent. Use of local anesthetics and corticosteroids was subject to restrictions and thus these were also monitored. Administration of the peptide hormone human choriogonadotropin (hCG), which stimulates the production of testosterone in the gonad, was banned, so we tested samples from male athletes for this hormone. At the end of the Games, at the request of the IOC Medical Commission, we screened all urine samples for cannabinoids. Samples have been tested for stimulants, narcotic analgesics, and anabolic steroids at the Olympic Games for some years, but the scope of drug testing was expanded markedly after the 1984 Olympic Summer Games in Los Angeles (1). At the Olympic Games in Calgary, p-blockers, diuretics, probenecid, cannabinoids, corticosteroids, and hCG were tested for the first time.
We tested samples from selected athletes for five classes of drugs, namely, stimulants, narcotic analgesics, anabolic steroids, p-blockers, and diuretics. Examples of drugs in these classes are presented in Table 1 . We also tested for probenecid, which has been used in sports as a masking agent. Use of local anesthetics and corticosteroids was subject to restrictions and thus these were also monitored. Administration of the peptide hormone human choriogonadotropin (hCG), which stimulates the production of testosterone in the gonad, was banned, so we tested samples from male athletes for this hormone. At the end of the Games, at the request of the IOC Medical Commission, we screened all urine samples for cannabinoids. Samples have been tested for stimulants, narcotic analgesics, and anabolic steroids at the Olympic Games for some years, but the scope of drug testing was expanded markedly after the 1984 Olympic Summer Games in Los Angeles (1) . At the Olympic Games in Calgary, p-blockers, diuretics, probenecid, cannabinoids, corticosteroids, and hCG were tested for the first time.
Local anesthetics and corticosteroids could be administered via certain routes, but such use had to be reported before drug testing. Intravenous and intramuscular injections of these drugs, as well as oral ingestion, were not permitted.
Materials and Methods

Organization
The laboratory staff was divided into three groups, each of which had eight technical staff members and could operate the laboratory independently. One staff member received and aliquoted samples and ran immunoassays; one analyzed for stimulants; one analyzed for pemoline, caffeine, and diuretics; two analyzed for narcotic analgesics and /3-blockers; two analyzed for anabolic steroids; and one senior staff member reviewed results. The overall operation was directed by the head of the Medical Control Laboratory (S.C.C.). Additionally, p-hCG was analyzed by RIA in the Endocrine Laboratory, at a separate location from the Medical Control Laboratory.
The laboratory operated in two 12-h shifts per day, from 1000 to 2200 hand 2200 to 1000 h, each serviced by one group of staff. The groups rotated between morning and evening shifts, with time off during shift change. A report of results for samples received the previous 
Phentermine
Sample Reception and Chain of Custody Each urine sample was divided and stored in two glass bottles, marked "A" and "B", after collection at the control station located at the competition venue. The bottles were placed in plastic bags marked A and B, respectively, which were then sealed and delivered to the laboratory by courier. Urine in the A bottle was used in the initial analysis; urine in the B bottle was analyzed only if that in the A bottle gave a positive result and the Medical Commission decided to impose sanctions against the athlete involved.
One laboratory staff member received samples from the courier, with another staff member present to witness the process. The integrity of the bags was inspected, and the B bags were given to the head of laboratory for safekeeping.
Next, the staff member broke the seal of the A bag and opened the bottle. We analyzed samples in batches of 10, plus a blank and a quality-control sample. The qualitycontrol sample, an open sample, was a blank urine sample supplemented with drugs appropriate to the analytical procedure.
Instrumentation
The laboratory was equipped with 14 Hewlett-Packard (Palo Alto, CA) chromatographic systems, including five Model 5890 gas chromatographs (GCs) with nitro- '4 
Analytical Procedures
We used two sets of screening procedures, one applicable to all samples (A1-A6) and the other for special situations (B1-B4). We confirmed any suspicious results by a more sophisticated procedure, generally involving MS. We screened all samples for stimulants, narcotic analgesic8, anabolic steroids, and cannabinoids. Samples were screened for /3-blockers (Bi) only for athletes in the following events: biathlon, bobsled, compulsory figure skating, luge, and ski jumping.
We tested for diuretics only when urine pH was >7.0 or its relative density was <1.010. Some diuretics (e.g., acetazolamide) tend to increase the alkalinity of urine, whereas many diuretics decrease its relative density. When the sample pH was >7.0, we screened for diuretics (B2) by HPLC. When the relative density was <1.010, we used a CC/MS procedure (B2 and B3). Only samples from male athletes were screened for f3-hCG by RIA.
Screening procedures for stimulants, narcotic analgesics, and anabolic steroids were well established (2) (3) (4) . The HPLC procedure for analysis of pemoline was as described elsewhere (5). We developed the procedure for diuretics analysis in our laboratory (6) . Probenecid and its metabolites were detectable in the diuretics procedure. The screening procedure for /3-blockers evolved from that for narcotic analgesics, except that we used CC/MS. Local anesthetics were analyzed by the method for stimulants, and we developed a special procedure to monitor synthetic corticosteroids.
Screening Procedures and Protocols
Al.
Stimulants:
We analyzed for stimulants in urine by GC/NPD. The drugs were extracted from the alkalinized urine into an organic solvent, diethyl ether, and injected via the splitless mode into the CC, which was fitted with a DB-1 (J & W Scientific, Inc., Folsom, CA) capillary column. The drug present was initially identified by its relative retention time (RRT), relative to that of the internal standard diphenylamine.
Alkaline urine inhibits the excretion of some basic drugs such as amphetamines (7) . Therefore, for urine samples with pH >6.5, we reduced the volume of the extract before analysis by GC to increase the sensitivity of the assay.
Because the expected concentration of strychnine in a positive sample is low and its retention time long, it is difficult to detect. To improve its detectability, we performed a separate GC run after the extract was concentrated, using a shorter column and a faster temperature program.
A sample chromatogram from analysis for stimulants is illustrated in Figure 1 . Many narcotic analgesics and /3-blockers are also detectable with this procedure.
Any unknown peak in the screening chromatogram was subjected to confirmation by MS. The extract was re-injected into a GC/MS, and the mass spectrum of the suspicious peak acquired. We identified the peak by comparing it with the mass spectrum of the suspected substance in the reference spectra library. 
A2. Narcotic analgesics:
This procedure, designed primarily for detecting narcotic analgesics, was also useful for detecting polar compounds with active hydroxy and amino functional groups, (e.g., 13-blockers and some stimulants). These functional groups must be modified to improve ,their chromatographic properties. Many drugs detectable by this procedure are excreted both as the free (unconjugated) form and as glucuronides and sulfates. Consequently, we designed two separate processes of extraction: the free drugs were extracted by a one-step process; the conjugates were first deconjugated by acid hydrolysis and then extracted. We then pooled the extracts and derivatized the drugs with trifluoroacetic anhydride before analysis. The internal standard in this procedure was phenazine. Screening was performed by GC/NPD and confirmation was by GCIMS, similar to the procedures for stimulants. A sample chromatogram of drugs detectable by this procedure is illustrated in Figure 2 .
A3. Pemoline and caffeine: Pemoline is not amenable to CC analysis by the stimulants screening procedure (Al), so we analyzed it by HPLC after extraction from the alkalinized urine. Detection was by spectrophotometry. We also used this procedure to quantify caffeine.
Pemoline was identified initially by its RRT to the internal standard in the HPLC system, proxyphylline, and by its ultraviolet spectrum. Confirmation was by CC/MS. Pemoline [2-amino-5-phenyl-4(5H)-oxazoloneJ was converted into its 2-hydroxy analog by acid hydrolysis, and then treated by extractive methylation with iodomethane and a phase-transfer reagent, tetrabutylammonium hydrogen sulfate (mAils). We defined a positive caffeine analysis as one in which the urinary concentration of caffeine exceeded 12 mg/L. If the initial screening indicated that the caffeine concentration might exceed the cutoff, we re-extracted the sample and analyzed it with a set of caffeine calibration standards. 
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125. to its TMS form, as described for BE.
Bi. a-blockers:
We screened for a-blockers by reinjecting the extract from the narcotic analgesics procedure (A2) into a CC/MS operating in the selected ion monitoring mode. iometric assay diagnostic kit (Organon Teknika Corp., Durham, NC) with a murine monoclonal antibody and 'I label. if the concentration of p-hCG was >20 mt. units/L, we performed a confirmation test, a doubleantibody I RIA (Diagnostic Products Corp., Los Angeles, CA).
Results and Discussion
The laboratory received 428 samples during the Games. Among these were five 'blind" quality-control samples submitted by the IOC Medical Commission to test the accuracy of the laboratory. These samples were all identified correctly.
The most samples, 108, were from the ice hockey competition, and a much smaller number, 18 each, came from the biathlon, nordic combined, and ski jumping events ( Table 2) . Testing was evenly spaced during the Cames, the heaviest daily work load we encountered being 38 samples.
Samples arrived at the laboratory in good time, with -50% in by 1800 h. The average turnaround time of a sample was 17 h, counting from the time the courier arrived at the laboratory. In most cases, we delivered results to the IOC Medical Commission in time for their nightly meetings about competitions held the previous day.
Of the 428 samples, 318 were from male athletes. Table 3 shows the distribution of pH values of the urine samples; the majority (97%) were acidic. There were 41 samples with pH >6.5, thus requiring special treatment in the stimulants procedure (Al). The distribution of relative density is also presented in Table 3 .
One-fourth of the athletes chosen for drug analysis declared they did not use any medication. The percentage of positive results was very close to the 20% found in the previous Olympic Winter Games (9) .
The 16 positive analyses of banned drugs reported to the Medical Commission are listed in Table 4 . Only one sample, a urine sample with a high testosterone/epitestosterone ratio, required analysis of the urine in the B sample had a caffeine concentration of 11.6 mg/L. Such a high value most likely came from the intake of caffeine pills, rather than from caffeine-containing beverages. However, because the administrative cutoff for a positive caffeine sample was 12 mg/L, we reported this sample as negative.
Of the 318 p-hCG assays we performed, only one sample was markedly increased: 16.9 int. unitsfL. After 
